Nabriva Therapeutics plc (NASDAQ:NBRV) enters into a definitive agreement with certain institutional investors

Nabriva Therapeutics plc (NBRV) changed -25.58% to recent value of $1.28. The stock transacted 12542824 shares during most recent day however it has an average volume of 765.51K shares. It spotted trading -60.86% off 52-week high price. On the other end, the stock has been noted 14.29% away from the low price over the last 52-weeks.

On Dec. 20, 2019, Nabriva Therapeutics plc (NASDAQ:NBRV) a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, notified that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering of (i) an aggregate of 13,793,106 ordinary shares and (ii) warrants to purchase up to an aggregate of 13,793,106 ordinary shares.  Each ordinary share and accompanying warrant are being sold together at a combined purchase price of $1.45.  The warrants have an exercise price of $1.90 per share, are initially exercisable six months following issuance (the Initial Exercise Date) and will expire on the 3-year anniversary of the Initial Exercise Date.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to Nabriva Therapeutics from the offering, before deducting the placement agent’s fees and other estimated offering expenses payable by Nabriva Therapeutics, are approximately $20 million.  The offering is expected to close on or about December 24, 2019, subject to the satisfaction of customary closing conditions.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

NBRV has a gross margin of 99.80%. Its earnings per share (EPS) expected to touch remained 9.30% for this year.

The company has 79.71M of outstanding shares and 77.84M shares were floated in the market. According to the most recent quarter its current ratio was 5.8 that represents company’s ability to meet its current financial obligations. The price moved ahead of -31.46% from the mean of 20 days, -32.71% from mean of 50 days SMA and performed -43.23% from mean of 200 days price. Company’s performance for the week was -26.86%, -30.05% for month and YTD performance remained -12.33%.

Leave a Reply

Your email address will not be published. Required fields are marked *